Cargando…

Phenformin has anti-tumorigenic effects in human ovarian cancer cells and in an orthotopic mouse model of serous ovarian cancer

Obesity and diabetes have been associated with increased risk and worse outcomes in ovarian cancer (OC). The biguanide metformin is used in the treatment of type 2 diabetes and is also believed to have anti-tumorigenic benefits. Metformin is highly hydrophilic and requires organic cation transporter...

Descripción completa

Detalles Bibliográficos
Autores principales:	Jackson, Amanda L., Sun, Wenchuan, Kilgore, Joshua, Guo, Hui, Fang, Ziwei, Yin, Yajie, Jones, Hannah M., Gilliam, Timothy P., Zhou, Chunxiao, Bae-Jump, Victoria L.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Impact Journals LLC 2017
Materias:	Research Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5725006/ https://www.ncbi.nlm.nih.gov/pubmed/29245964 http://dx.doi.org/10.18632/oncotarget.22012

Ejemplares similares

Asparagus officinalis Exhibits Anti-Tumorigenic and Anti-Metastatic Effects in Ovarian Cancer
por: Xu, Guangxu, et al.
Publicado: (2021)

Anti-Tumor and Anti-Invasive Effects of ONC201 on Ovarian Cancer Cells and a Transgenic Mouse Model of Serous Ovarian Cancer
por: Fan, Yali, et al.
Publicado: (2022)

Everolimus exhibits anti-tumorigenic activity in obesity-induced ovarian cancer
por: Guo, Hui, et al.
Publicado: (2016)

Dual inhibition of glycolysis and glutaminolysis as a therapeutic strategy in the treatment of ovarian cancer
por: Sun, Li, et al.
Publicado: (2017)

Inhibition of CDK1 by RO-3306 Exhibits Anti-Tumorigenic Effects in Ovarian Cancer Cells and a Transgenic Mouse Model of Ovarian Cancer
por: Huang, Yu, et al.
Publicado: (2023)

The HMG-CoA reductase inhibitor, simvastatin, exhibits anti-metastatic and anti-tumorigenic effects in ovarian cancer
por: Stine, Jessica E., et al.
Publicado: (2015)

The effect of celecoxib on tumor growth in ovarian cancer cells and a genetically engineered mouse model of serous ovarian cancer
por: Suri, Anuj, et al.
Publicado: (2016)

NT1014, a novel biguanide, inhibits ovarian cancer growth in vitro and in vivo
por: Zhang, Lu, et al.
Publicado: (2016)

Orlistat exerts anti-obesity and anti-tumorigenic effects in a transgenic mouse model of endometrial cancer
por: Xu, Guangxu, et al.
Publicado: (2023)

SPR965, a Dual PI3K/mTOR Inhibitor, as a Targeted Therapy in Ovarian Cancer
por: Tran, Arthur-Quan, et al.
Publicado: (2021)

JQ1 suppresses tumor growth through downregulating LDHA in ovarian cancer*
por: Qiu, Haifeng, et al.
Publicado: (2015)

The Capacity of High-Grade Serous Ovarian Cancer Cells to Form Multicellular Structures Spontaneously along Disease Progression Correlates with Their Orthotopic Tumorigenicity in Immunosuppressed Mice
por: Goyeneche, Alicia, et al.
Publicado: (2020)

ARHGAP10, downregulated in ovarian cancer, suppresses tumorigenicity of ovarian cancer cells
por: Luo, N, et al.
Publicado: (2016)

Phenformin as prophylaxis and therapy in breast cancer xenografts
por: Appleyard, M V C L, et al.
Publicado: (2012)

ONC206, an Imipridone Derivative, Induces Cell Death Through Activation of the Integrated Stress Response in Serous Endometrial Cancer In Vitro
por: Zhang, Yingao, et al.
Publicado: (2020)

Ipatasertib exhibits anti-tumorigenic effects and enhances sensitivity to paclitaxel in endometrial cancer in vitro and in vivo
por: O'donnell, Jillian, et al.
Publicado: (2023)

Synergistic Anti-Cancer Effect of Phenformin and Oxamate
por: Miskimins, W. Keith, et al.
Publicado: (2014)

Asparagus officinalis combined with paclitaxel exhibited synergistic anti-tumor activity in paclitaxel-sensitive and -resistant ovarian cancer cells
por: Zhang, Xin, et al.
Publicado: (2022)

Aberrant over-expression of COX-1 intersects multiple pro-tumorigenic pathways in high-grade serous ovarian cancer
por: Wilson, Andrew J., et al.
Publicado: (2015)

Notch signaling in serous ovarian cancer
por: Groeneweg, Jolijn W, et al.
Publicado: (2014)

Glutamine promotes ovarian cancer cell proliferation through the mTOR/S6 pathway
por: Yuan, Lingqin, et al.
Publicado: (2015)

Evaluation of the antitumor effects of c-Myc-Max heterodimerization inhibitor 100258-F4 in ovarian cancer cells
por: Wang, Jiandong, et al.
Publicado: (2014)

Ipatasertib, an oral AKT inhibitor, in combination with carboplatin exhibits anti-proliferative effects in uterine serous carcinoma
por: Burkett, Wesley C., et al.
Publicado: (2023)

BRCA and Early Events in the Development of Serous Ovarian Cancer
por: George, Sophia H. L., et al.
Publicado: (2014)

Prediction of chemo-response in serous ovarian cancer
por: Gonzalez Bosquet, Jesus, et al.
Publicado: (2016)

Mutational heterogeneity in non-serous ovarian cancers
por: Teer, Jamie K., et al.
Publicado: (2017)

Fallopian tube secreted protein affects ovarian metabolites in high grade serous ovarian cancer
por: Bergsten, Tova M., et al.
Publicado: (2022)

TRRAP stimulates the tumorigenic potential of ovarian cancer stem cells
por: Kang, Kyung Taek, et al.
Publicado: (2018)

An Advanced Orthotopic Ovarian Cancer Model in Mice for Therapeutic Trials
por: Zhang, Ying, et al.
Publicado: (2016)

Phenformin as an Anticancer Agent: Challenges and Prospects
por: García Rubiño, Mª Eugenia, et al.
Publicado: (2019)

Function of m(5)C RNA methyltransferase NOP2 in high-grade serous ovarian cancer
por: Yang, Shimin, et al.
Publicado: (2023)

Orthotopic and heterotopic ovarian tissue transplantation
por: Demeestere, I., et al.
Publicado: (2009)

Evaluation of the anti-tumor effects of lactate dehydrogenase inhibitor galloflavin in endometrial cancer cells
por: Han, Xiaoyun, et al.
Publicado: (2015)

Targeting the Microenvironment in High Grade Serous Ovarian Cancer
por: Nwani, Nkechiyere G., et al.
Publicado: (2018)

The Tumor Microenvironment of High Grade Serous Ovarian Cancer
por: Stack, M. Sharon, et al.
Publicado: (2018)

Cell Origins of High-Grade Serous Ovarian Cancer
por: Kim, Jaeyeon, et al.
Publicado: (2018)

Proteome profiling of low grade serous ovarian cancer
por: zadeh fakhar, Haniyeh Bashi, et al.
Publicado: (2019)

High-grade serous ovarian cancer: the clone wars
por: Salomon-Perzyński, Aleksander, et al.
Publicado: (2017)

Outcome in serous ovarian cancer is not associated with LATS expression
por: Montavon, Céline, et al.
Publicado: (2019)

BDP1 as a biomarker in serous ovarian cancer
por: Cabarcas‐Petroski, Stephanie, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_a3tjjf27uc9bfbfonokp4tqsj3